Impact of Body Mass Index of Japanese Gallbladder Cancer Patients on their Postoperative Outcomes by Fujii, Masakuni et al.
G allbladder cancer (GBC) is the most common malignancy of the biliary tract,  accounting for 
80‒95% of biliary tract cancers worldwide [1-3].  GBC 
ranks fifth among gastrointestinal cancers,  and is tradi-
tionally regarded as a highly lethal disease,  with an 
overall 5-year survival rate of less than 5%.  The overall 
mean survival time for patients with GBC is 6 months.  
GBC is highly fatal and usually diagnosed at advanced 
stages due to the absence of specific clinical findings in 
the early stages [4-8].  It has been reported that the 
age-adjusted incidence rate of GBC is 1.4 per 100,000 in 
the U.S.,  and steadily increases with age [9].  Despite 
recent advances in diagnostic techniques and therapeu-
tic management,  the prognosis for patients with GBC 
remains dismal.
Many studies have reported multiple factors closely 
related to GBC,  such as gallstones,  alcohol consump-
tion,  smoking,  blood glucose and diabetes mellitus 
(DM),  genetic susceptibility,  and obesity [10-12].  In 
recent years,  it has become apparent that overweight 
and obesity,  as defined by body mass index (BMI),  is a 
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We investigated the relationship between body mass index (BMI) and postoperative outcomes in 450 gallblad-
der cancer patients in Japan.  We collected patient information,  including sex,  age,  underlying disease,  BMI,  
stage,  surgery method,  postoperative time to discharge,  and postoperative Medicare fees,  from the Japanese 
administrative database associated with the Diagnosis Procedure Combination system.  We classified patient 
BMIs as underweight (BMI < 18.5 kg/m2),  normal (BMI ≥ 18.5 kg/m2 and < 25 kg/m2) or overweight/obese 
(BMI ≥ 25 kg/m2),  then investigated the relationship between these categories and two postoperative out-
comes: time to discharge and postoperative Medicare fees.  The median postoperative time to discharge was 
12 days in all patients,  and 12 days in each of the three weight groups (p= 0.62,  n.s.).  The median postoperative 
Medicare fees from surgery until discharge were (USD): all patients,  $5,002; underweight,  $5,875; normal 
weight,  $4,797; and overweight/obese,  $5,179 (p= 0.146,  n.s.).  A multivariate analysis with adjustment for 
competing risk factors revealed that BMI was not associated with increased risk of longer postoperative time to 
discharge (normal weight: HR 1.17,  p= 0.29; overweight/obese: HR 1.17,  p= 0.37) or higher postoperative 
Medicare fees (OR 0.99,  p= 0.86,  n.s.).  Thus,  high BMI was not found to be a factor for poor postoperative 
outcomes in Japanese patients with gallbladder cancer.
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risk factor for GBC.  This is particularly true in mid-
dle-aged women [13].  The number of overweight indi-
viduals has increased dramatically worldwide; it is 
estimated that today there are approximately 1.6 billion 
individuals who are overweight and 400 million who 
are obese [14, 15].  High BMI—both overweight and 
obesity—is a well-recognized risk factor for several 
chronic degenerative diseases,  such as cardiovascular 
disease and diabetes,  and for numerous types of cancer,  
including GBC.  According to the most recent 2014 
Cancer Progress Report from the American Association 
for Cancer Research,  a high BMI is responsible for 
nearly 25% of the relative contribution to cancer inci-
dence,  ranking second only to tobacco use [16, 17].
There are few reports regarding the effects of high 
BMI on the outcomes of surgery for GBC,  and a con-
sensus has not been reached.  The number of over-
weight patients who undergo surgery for GBC has 
increased,  but data concerning short-term and long-
term outcomes for this procedure in overweight 
patients are lacking.  There is also little information 
about the relationship between BMI and the postopera-
tive outcomes of Japanese GBC patients in particular.  
The survival time of GBC is short,  so the level of dis-
ease progression upon admission for surgery has a great 
effect on the overall progression.  
In the present study,  we used the Japanese adminis-
trative database associated with the Diagnosis 
Procedure Combination (DPC) system to examine the 
relationship between preoperative BMI and postopera-
tive time to discharge and postoperative Medicare fees 
in Japanese GBC patients who underwent surgery.  The 
DPC is the original Japanese case-mix classification sys-
tem,  in which each case has a code consisting of diag-
nosis and treatment procedures.  Per diem payments 
vary according to the length of hospitalization,  which is 
determined for each code.  The system was developed to 
standardize and evaluate the cost and quality of medical 
services in Japan.  One of the advantages of the DPC is 
that the data can be collected in a common electronic 
format [18-21].
Patients and Methods
Patients. We selected the cases of 450 patients 
with GBC who were > 30 years old from the National 
Saiseikai Hospital DPC survey between April 2011 and 
March 2017.  The principal diagnosis of GBC was 
recorded using the International Classification of 
Diseases and Injuries (ICD)-10th code edition.  In the 
present analysis,  GBC was defined as code C23 in the 
ICD-10th code edition.  We excluded 84 cases for which 
the stage of disease was unclear.
Methods. From the DPC data we extracted data 
on age,  sex,  underlying disease,  BMI,  disease stage,  
operative method,  postoperative duration of antibiotic 
therapy,  postoperative time to discharge,  and postop-
erative Medicare fee for the 450 patients with GBC.  
Each patient’s BMI was calculated as weight in kilo-
grams (kg) divided by height in meters squared (m2),  
both of which were measured upon admittance to the 
hospital for GBC surgery.  For the analyses,  we divided 
the patients into three groups based on their BMI values 
as described by the World Health Organization classifi-
cation: underweight (BMI<18.5 kg/m2),  normal weight 
(BMI ≥ 18.5 kg/m2 and < 25 kg/m2),  and overweight/
obese (BMI ≥ 25 kg/m2).  The GBC stage was defined by 
the Union for International Cancer Control (UICC) 
classification system.  Regarding the operative method,  
a laparoscopic or open cholecystectomy,  minor 
liver resection,  major liver resection,  or hepatopancre-
atoduodenectomy was performed.  Laparoscopic or 
open cholecystectomy and minor liver resection were 
treated as less aggressive surgery while major liver 
resection and hepatopancreatoduodenectomy were 
treated as highly aggressive surgery.  Postoperative out-
comes were evaluated based on the median time of 
antibiotic therapy after the operation,  the postoperative 
median time to discharge and the postoperative 
Medicare fee.  The antibiotic therapy after the operation 
was performed for about 1-3 days in all cases except one 
for the prevention of surgical site infection.  For the 
single case with symptoms of infection,  antibiotics were 
administered for a longer period.
Statistical methods. Statistical analyses were per-
formed with STATA 13 software (StataCorp,  College 
Station,  TX,  USA).  Student’s t-test was used to com-
pare the means of the continuous variables,  and Fisher’s 
exact test was used to compare the frequencies of the 
categorical variables between groups.  The Kaplan-
Meier method and log-rank test were used to analyze 
the time of antibiotic therapy after the operation and the 
postoperative time to discharge (time from surgery until 
discharge,  regardless of cause).  After we performed a 
univariate analysis,  we subjected the significant vari-
ables to a multivariate analysis using a Cox propor-
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tional hazards model.  An analysis of variance 
(ANOVA) was used to compare the postoperative 
Medicare fees in the different BMI groups.  A logistic 
analysis was used to determine independent factors 
associated with the postoperative Medicare fee.  We 
accepted p-values < 0.05 as significant.  The research 
protocol of the study was approved by the Institutional 
Review Board at Okayama Saiseikai General Hospital 
(no. 170509).
Results
The patients’ background characteristics are pre-
sented in Table 1.  Within the group of 450 patients,  
12.2% (n = 55) were underweight,  68.7% (n = 309) were 
normal weight,  and 19.1% (n = 86) were overweight/
obese.  The sex ratio (numbers of males/females) was 
25/30 in the underweight group,  146/163 in the normal 
weight group,  and 49/37 in the overweight/obese group 
(p = 0.24).  The median (range) age of the patients was 
74 (43-89) years in the underweight group,  73 (33-94) 
years in the normal weight group,  and 70 (30-91) years 
in the overweight/obese group (p = 0.62).  No significant 
differences in underlying disease,  such as hypertension,  
hyperlipidemia,  or DM,  were observed among the three 
groups.  
The disease stage of the GBC cases (I/II/IIIA vs.  
IIIB/IV) was 50/5 patients in the underweight group,  
281/28 patients in the normal weight group,  and 75/11 
patients in the overweight/obese group (p = 0.58).  The 
surgery (open/laparoscopic surgery) was 52/3 patients 
in the underweight group,  282/27 patients in the nor-
mal weight group,  and 75/11 patients in the over-
weight/obese group (p = 0.31).  In terms of operative 
method,  the ratios of less aggressive surgery to highly 
aggressive surgery were 51/4 patients in the under-
weight group,  290/19 patients in the normal weight 
group,  and 80/6 patients in the overweight/obese group 
(p = 0.93).  Postoperative blood transfusion was per-
formed in 5 of the 450 patients (1.1%).  Six of the 450 
patients died during hospitalization after surgery 
(1.3%).  There were no significant differences in postop-
erative blood transfusion or mortality during hospital-
ization after surgery among the three BMI groups.  
The duration of postoperative antibiotic therapy was 
3 days in all patients,  and 5,  3 and 5 days in the under-
weight,  normal weight and overweight/obese groups,  
respectively.  Log-rank tests showed significance for 
each group (p = 0.028).  The postoperative time to dis-
charge was 12 days in all patients,  and 12 days in all 
three BMI groups (Fig. 1).  Log-rank tests showed no 
significant differences among any of the groups (p=0.62).  
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Table 1 Baseline characteristics of the study population
No. (％)
p-value
All patients Underweight Normal weight Overweight/obese
No. of patients 450 55 (12.2) 309 (68.7) 86 (19.1)
Population Characteristics
Sex (male) 220 (48.9) 25 (11.3) 146 (66.4) 49 (22.3) 0.24
Age (median,  y)  73 74  73 70 0.62
Underlying disease
Hypertension 141 (31.3) 10 (18.2) 106 (34.3) 25 (29.1) 0.05
Hyperlipidemia  72 (16)  7 (12.7)  55 (17.8) 10 (11.6) 0.3
Diabetes mellitus  88 (19.6)  9 (16.4)  57 (18.4) 22 (25.6) 0.27
Stage (UICC) 0.58
Stage I,  II,  IIIA 406 (90.2) 50 (12.3) 281 (69.2) 75 (18.5)
Stage IIIB,  IV  44 (9.8)  5 (11.4)  28 (63.6) 11 (25.0)
Surgery 0.31
Laparoscopic  41 (9.1)  3 (7.3)  27 (65.9) 11 (26.8)
Open 409 (90.9) 52 (12.7) 282 (69.0) 75 (18.3)
Operative method 0.93
Less aggressive (laparoscopic or opened
Cholecystectomy,  minor liver resection) 421 (93.6) 51 (12.1) 290 (68.9) 80 (19.0)
Highly aggressive (major liver resection,  
hepatopancreatoduodenectomy)
 29 (6.4)  4 (13.8)  19 (65.5)  6 (20.7)
Mortality   6 (1.3)  1 (16.7)   4 (66.7)  1 (16.7) 0.95
The median postoperative Medicare fees from surgery 
until discharge were as follows (USD) ($1=110 yen):  
all patients,  $5,002; underweight,  $5,875; normal 
weight,  $4,797; and overweight/obese,  $5,179 (p=0.146) 
(Table 2).  
With respect to stage,  the duration of postoperative 
antibiotic therapy was 3 days in all patients,  3 days in 
the stage I/II/IIIA group,  and 9 days in the stage IIIB/
IV group.  Log-rank tests showed a significant differ-
ence between the 2 groups (p < 0.0001).  The postopera-
tive time to discharge was 12 days in all patients,  
12 days in the stage I/II/IIIA group,  and 20 days in the 
stage IIIB/IV group.  Log-rank tests showed a significant 
difference between the 2 groups (p < 0.0001).  The 
median postoperative Medicare fee from surgery until 
discharge was as follows (USD) : all patients,  
$5,002; stage I/II/IIIA,  $4,563; and stage IIIB/IV,  
$9,054 (p < 0.001) (Table 3).  
In the comparison of operative methods,  the dura-
tion of postoperative antibiotic therapy was 3 days in all 
patients,  3 days in the less aggressive surgery group,  
and 10 days in the highly aggressive surgery group.  
Log-rank tests showed a significant difference between 
groups (p = 0.0006).  The postoperative time to dis-
charge was 12 days in all patients,  12 days in the less 
aggressive surgery group,  and 19 days in the highly 
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Table 2 Outcome according to BMI
No. of patients Time of antibiotic therapy after the operation (days) (95%CI)
Postoperative time to  
discharge (days) (95%CI)
The median postoperative 
Medicare fees ($)
All patients 450 3 (3-4) 12 (11-12) 5,002
Underweight  55 5 (3-6) 12 (11-14) 5,875
Normal weight 309 3 (3-3) 12 (11-12) 4,797
Overweight/Obese  86 5 (3-6) 12 (10-14) 5,179
p-value 0.028 0.62 0.146
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Fig. 1 Postoperative time to discharge according to BMI  
According to BMI,  the postoperative time to discharge was 12 days in all patients,  12 days in the underweight group,  12 days in the normal 
weight group,  and 12 days in the overweight/obese group.  Log-rank testing did not show signiﬁcant diﬀerences among any of the groups 
(p=0. 62).
aggressive surgery group.  Log-rank tests showed a sig-
nificant difference between groups (p < 0.0001).  The 
median postoperative Medicare fees from surgery until 
discharge were as follows (USD): all patients,  
$5,002; less aggressive surgery,  $4,580; and highly 
aggressive surgery,  $11,130 (p < 0.001) (Table 4).  
The univariate analysis for duration of postoperative 
antibiotic therapy identified the disease stage (I/II/IIIA 
vs.  IIIB/IV) (hazard ratio [HR] 0.52,  95% confidence 
interval [CI] 0.37-0.72,  p < 0.001) and operative method 
(less aggressive surgery vs.  highly aggressive surgery) 
(HR 0.54,  95%CI 0.36-0.80,  p = 0.002) as significant 
predictors.  The multivariate analysis indicated that the 
same two factors were significantly associated with the 
postoperative outcomes: disease stage (I/II/IIIA vs.  
IIIB/IV) (HR 0.56,  95%CI 0.40-0.78,  p = 0.001) and 
operative method (less aggressive surgery vs.  highly 
aggressive surgery) (HR 0.62,  95%CI 0.41-0.93,  p=0.019) 
(Table 5).  
The univariate analysis identified as significant pre-
dictors of postoperative time to discharge both disease 
stage (I/II/IIIA vs.  IIIB/IV) (HR 0.51,  95%CI 0.37-0.71,  
p < 0.001) and operative method (less aggressive surgery 
vs.  highly aggressive surgery) (HR 0.41,  95%CI 0.27-
0.61,  p < 0.001).  The multivariate analysis indicated that 
the same two factors were significantly associated with 
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Table 3 Outcome according to stage
No. of patients Time of antibiotic therapy after the operation (days) (95%CI)
Postoperative time to  
discharge (days) (95%CI)
The median postoperative 
Medicare fees ($)
All patients 450 3 (3-4) 12 (11-12) 5,002
Stage I, II, IIIA 406 3 (3-4) 12 (11-12) 4,563
Stage IIIB, IV  44 9 (4-12) 20 (15-25) 9,054
p-value ＜0.0001 ＜0.0001 ＜0.001
Table 4 Outcome according to operative method
No. of patients Time of antibiotic therapy after the operation (days) (95%CI)
Postoperative time to  
discharge (days) (95%CI)
The median postoperative 
Medicare fees ($)
All patients 450 3 (3-4) 12 (11-12) 5,002
Less aggressive surgery 421 3 (3-4) 12 (11-12) 4,580
Highly aggressive surgery  29 10 (4-11) 19 (15-37) 11,130
p-value 0.0006 ＜0.0001 ＜0.001
Table 5 Factors related to the duration of postoperative antibiotic therapy for Japanese patients with gallbladder cancer
Variable
Univariate analysis Multivariate analysis
Hazard ratio 95%CI p-value Hazard ratio 95%CI p-value
Sex
Male 1 1
Female 1.08 0.89-1.30 0.428 1.05 0.87-1.27 0.580
Age (year)
＜80 1
≧80 1.12 0.90-1.39 0.321 1.13 0.91-1.41 0.266
Stage (UICC)
Stage I, II, IIIA 1 1
Stage IIIB, IV 0.52 0.37-0.72 ＜0.001 0.56 0.40-0.78 0.001
Operative method
Less aggressive 1 1
Highly aggressive 0.54 0.36-0.80 0.002 0.62 0.41-0.93 0.019
BMI
Underweight 1 1
Normal weight 1.31 0.98-1.77 0.064 1.33 0.99-1.79 0.059
Overweight/Obese 1.05 0.74-1.48 0.793 1.10 0.78-1.56 0.581
postoperative outcomes: disease stage (I/II/IIIA vs.  
IIIB/IV) (HR 0.58,  95%CI 0.41-0.80,  p = 0.001) and 
operative method (less aggressive surgery vs.  highly 
aggressive surgery) (HR 0.45,  95%CI 0.30-0.68,  
p < 0.001) (Table 6).  
The univariate analysis for postoperative Medicare 
fees from surgery until discharge identified disease stage 
(I/II/IIIA vs.  IIIB/IV) (OR 1.84,  95%CI 1.56-2.17,  
p < 0.001) and operative method (less aggressive surgery 
vs.  highly aggressive surgery) (OR 2.50,  95%CI 1.89-
3.31,  p < 0.001) as significant predictors.  The multivar-
iate analysis indicated that the same 2 factors were sig-
nificantly associated with postoperative outcomes:  
disease stage (I/II/IIIA vs.  IIIB/IV) (OR 1.68,  95%CI 
1.41-2.00,  p < 0.001) and operative method (less aggres-
sive surgery vs.  highly aggressive surgery) (OR 2.16,  
95%CI 1.61-2.91,  p < 0.001) (Table 7).  Thus,  advanced 
disease stage and operative method were associated 
with poor postoperative outcomes.  An overweight/
obese BMI was not a factor for poor postoperative out-
comes.  In addition,  age and sex were not postoperative 
outcome factors.
Discussion
GBC,  a common malignant tumor in the digestive 
system,  has a high mortality rate and lacks diagnostic 
specificity,  posing a great challenge for preoperative 
and early-stage diagnosis.  The overall mean survival 
duration for patients with GBC is 6 months [22, 23].  
Previous studies highlighted extensive disease and the 
number of positive lymph nodes as important predic-
tors of worse outcomes [23-25].
 The incidence of GBC increases with age.  Europe 
has a low overall incidence of 0-4/100,000,  while Japan 
has a higher incidence at 7/100,000 [3, 8, 26].  The pres-
ent findings regarding GBC in Japan are thus especially 
useful.
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Table 7 Factors related to postoperative Medicare fees from surgery until discharge among Japanese patients with gallbladder cancer
Variable
Univariate analysis Multivariate analysis
Odds ratio 95%CI p-value Odds ratio 95%CI p-value
Sex 0.90 0.59-1.38 0.625 0.80 0.49-1.31 0.378
Age (year) 1.00 0.98-1.02 0.952 1.01 0.98-1.04 0.470
Stage (UICC) 1.84 1.56-2.17 ＜0.001 1.68 1.41-2.00 ＜0.001
Operative method 2.50 1.89-3.31 ＜0.001 2.16 1.61-2.91 ＜0.001
BMI 0.99 0.93-1.05 0.655 0.99 0.93-1.06 0.862
Table 6 Factors related to the postoperative time to discharge among Japanese patients with gallbladder cancer
Variable
Univariate analysis Multivariate analysis
Hazard ratio 95%CI p-value Hazard ratio 95%CI p-value
Sex
Male 1 1
Female 1.13 0.94-1.36 0.198 1.13 0.94-1.37 0.193
Age (year)
＜80 1
≧80 0.98 0.79-1.22 0.887 0.97 0.78-1.21 0.812
Stage (UICC)
Stage I, II, IIIA 1 1
Stage IIIB, IV 0.51 0.37-0.71 ＜0.001 0.58 0.41-0.80 0.001
Operative method
Less aggressive 1 1
Highly aggressive 0.41 0.27-0.61 ＜0.001 0.45 0.30-0.68 ＜0.001
BMI
Underweight 1 1
Normal weight 1.14 0.85-1.53 0.368 1.17 0.87-1.57 0.290
Overweight/Obese 1.09 0.77-1.53 0.637 1.17 0.83-1.65 0.366
The most significant risk factor for GBC is gallstones 
(relative risk [RR] = 3.0-23.8),  which are present in the 
majority (69-85%) of GBC patients.  Recently,  it was 
reported that obesity is a risk factor for GBC in mid-
dle-aged women [13].  
The following theories have been proposed regard-
ing the mechanism of GBC in obese patients.  Obesity 
could increase the prevalence of GBC by promoting the 
formation of gallstones and elevating blood glucose lev-
els.  Some studies have shown that retinol-binding pro-
tein 4 (RBP4) is closely associated with insulin resis-
tance and obesity.  Elevated RBP4 has been associated 
with an increased incidence of gallstone disease.  Wang 
et al.  reported that the level of bile RBP4 was correlated 
positively with BMI.  Therefore,  increased BMI may 
play a role in the course of gallstone formation and 
thereby influence the morbidity of GBC by elevating 
RBP4.  These interconnected pathways may suggest the 
pathophysiological mechanism of the obesity-cancer 
link [27-32].  Despite these suggested theories,  there 
have been few reports regarding the influence of excess 
body weight on the outcomes of GBC,  and the findings 
from these studies have been controversial.
There are few reports from Japan about the relation-
ship between BMI and the postoperative outcomes of 
GBC.  We investigated postoperative outcomes accord-
ing to BMI in a large sample of patients with GBC 
(n = 450) using a Japanese national DPC database.  Our 
analyses revealed that excess body weight was not a fac-
tor for poor outcomes in Japanese patients with GBC 
who underwent surgery.  On the other hand,  an 
advanced disease stage and highly aggressive surgery 
were poor outcome factors in terms of the postopera-
tive duration of antibiotic therapy,  postoperative time to 
discharge and postoperative Medicare fees.  We did not 
examine perioperative stress parameters,  such as the 
operation time or the amount of blood loss; however,  
the mortality rate during hospitalization after surgery 
was 1.3%,  which was low.  
We were not able to examine the details of the post-
operative complications of this series of patients with 
GBC.  There were very few postoperative deaths or 
blood transfusions during hospitalization,  and there 
were no significant differences among the BMI groups 
in terms of postoperative time to discharge,  postopera-
tive Medicare fees,  postoperative deaths or blood trans-
fusion during hospitalization.  
However,  log-rank testing did show significant dif-
ferences among the BMI groups in terms of antibiotic 
therapy after the operation.  Obesity is a high-risk factor 
for postoperative complications [33].  We suspect that in 
the present overweight/obesity group,  antibiotics were 
used for a longer time than in the normal BMI group,  
either for the prevention of postoperative infectious 
complications or because of their existence.  In addition,  
the underweight group might have included cases in 
particularly bad condition such as sarcopenia cases;  
hence,  antibiotics were used for a longer time than in 
the normal group for similar reasons.  However,  BMI 
was not an independent factor for the duration of post-
operative antibiotic therapy by multivariate analysis,  
and the differences among groups were only a few days.  
Accordingly,  the postoperative antibiotic therapy did 
not affect the postoperative time to discharge or postop-
erative Medicare fees.  
Highly aggressive surgery was an independent factor 
of both postoperative time to discharge and postopera-
tive Medicare fees.  We considered that highly aggres-
sive surgery caused the postoperative complications in 
those cases in which such complications arose.  
However,  the study had a preponderance of less aggres-
sive surgeries (93.6%).  Thus,  BMI was not shown to 
affect postoperative time to discharge or postoperative 
Medicare fees.  There were particularly few cases of 
pancreatoduodenectomy (1.1%) and thus we speculate 
that BMI did not contribute to postoperative complica-
tions that would affect postoperative time to discharge 
and postoperative Medicare fees.  Further studies 
enrolling more cases by each operative method will be 
needed in the future.
High BMI is a risk factor for GBC,  and appropriate 
weight control is important for GBC prevention.  For 
good postoperative outcomes,  it is also important to 
(1) educate obese patients regarding the risk of GBC,  
(2) identify GBC in the early stages during a routine 
medical check,  and (3) perform surgery as early as pos-
sible.  Consequently,  we suggest that it is better for 
overweight or obese patients with GBC to undergo sur-
gery as soon as possible,  rather than wait until after 
body weight loss.  
The greatest strength of the present study is its use of 
individual data.  One of the advantages of using the 
administrative database associated with the DPC system 
was that it allowed for the participation of a large num-
ber of acute-care hospitals; as a result,  our investiga-
tion enrolled a nationally representative sample of 
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patients in a community setting.  In addition,  medical 
data such as procedures,  drugs,  and devices were coded 
with the original Japanese payment codes for the DPC 
reimbursement system.  These data were recorded for 
each patient on a daily basis [18-21].  Therefore,  this 
administrative database enabled a detailed evaluation of 
patients with GBC based on individual medical treat-
ments.  
This study has some possible limitations.  The data-
base did not contain detailed patient information such 
as previous illness,  laboratory data,  image data after 
admission and peri-postoperative complications.  In 
addition,  because we could not examine the patients’ 
nutritional conditions in detail,  this issue must be 
addressed in the future.  The rate of obesity may vary by 
race; it was 19.1% in the current study,  and 57% in a 
Mexican study.  Similarly,  the rate of underweight in 
Westerners is much lower than that in the Japanese 
population.  The obese population in Japan is small 
compared to those in Europe and the U.S.  In Japan,  the 
obesity rate is reported to be 28.7% in males and 21.3% 
in females,  and the underweight rate is 4.5% in males 
and 10.4% in females [34].  Therefore,  a global analysis,  
especially concerning the relationship between BMI and 
postoperative outcomes of surgery for GBC,  would be 
useful.  In addition,  in this study,  stage IIIB or IV dis-
ease was present in 9.8% of the patients,  and highly 
aggressive surgery was carried out in 6.4%.  Few 
patients had advanced-stage disease; hence,  it was dif-
ficult to find statistical evidence of the effect of BMI in 
such patients.  Also,  we did not examine the use of 
adjuvant or neo-adjuvant chemotherapy.  Studies of 
GBC outcomes incorporating these points are expected 
in the future.  Furthermore,  in this study,  we examined 
short-term outcomes until discharge from surgery for 
GBC.  Examination of the long-term course,  including 
survival rates,  is also expected in the future.
In conclusion,  our study revealed that excess body 
weight does not significantly influence immediate post-
operative outcomes in Japanese patients with GBC who 
undergo surgery.  Specifically,  time to discharge and 
Medicare fees after surgery for GBC were not associated 
with BMI.  Additional studies are needed to investigate 
the influence of other factors on postoperative outcomes 
in GBC patients,  especially those with advanced stage 
or facing aggressive surgery.
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